GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Oncology/Short-Course Radiotherapy for Older Patients With Locally Advanced Rectal Cancer (SOFT Study)

Short-Course Radiotherapy for Older Patients With Locally Advanced Rectal Cancer (SOFT Study)

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated December 1, 2025

Quick Answer

The Short-Course Radiotherapy (SCRT) for Older Patients With Locally Advanced Rectal Cancer (SOFT Study) is a multicenter investigation focused on evaluating the effectiveness and feasibility of SCRT followed by delayed surgery as a treatment strategy for older patients with stage II–III rectal adenocarcinoma who are unfit for chemotherapy. This patient population often faces challenges in tolerating conventional long-course chemoradiotherapy due to age-related frailty, comorbidities, and reduced physiological reserve.


The Short-Course Radiotherapy (SCRT) for Older Patients With Locally Advanced Rectal Cancer (SOFT Study) is a multicenter investigation focused on evaluating the effectiveness and feasibility of SCRT followed by delayed surgery as a treatment strategy for older patients with stage II–III rectal adenocarcinoma who are unfit for chemotherapy. This patient population often faces challenges in tolerating conventional long-course chemoradiotherapy due to age-related frailty, comorbidities, and reduced physiological reserve. The SOFT study aimed to address these challenges by offering a potentially less burdensome yet effective therapeutic approach.

### Key Features of the SOFT Study:

1. **Patient Population**:

  • Older patients diagnosed with locally advanced rectal cancer (stage II–III rectal adenocarcinoma).
  • Patients deemed unfit for chemotherapy due to frailty, significant comorbidities, or other health-related limitations.

2. **Treatment Protocol**:

  • **Short-Course Radiotherapy (SCRT)**: Patients underwent a condensed schedule of radiotherapy, which is typically delivered over five consecutive days.
  • **Delayed Surgery**: After a planned interval following radiotherapy, patients proceeded to surgical resection of the tumor.

3. **Outcomes Assessed**:

  • **Tumor Response**: Both complete and partial tumor responses were observed, with evidence of tumor down-staging prior to surgery.
  • **Surgical Results**: High rates of complete tumor removal were achieved during surgery.
  • **Pathologic Tumor Eradication**: A subset of patients demonstrated complete tumor eradication, underscoring the biological effectiveness of SCRT.
  • **Survival Outcomes**: Long-term follow-up indicated encouraging disease control and survival rates.
  • **Safety and Tolerability**: Postoperative complications were deemed acceptable, and treatment-related mortality was low, highlighting the safety of the approach.

### Advantages of SCRT Followed by Delayed Surgery:

  • **Reduced Treatment Burden**: SCRT involves a shorter duration of radiotherapy compared to conventional chemoradiotherapy, making it more manageable for elderly patients.
  • **Oncologic Effectiveness**: The study demonstrated meaningful tumor control, with favorable rates of tumor down-staging and eradication.
  • **Improved Tolerability**: The approach was associated with limited toxicity and acceptable postoperative outcomes, making it a viable option for frail patients.
  • **Safety Profile**: Low treatment-related mortality and manageable side effects further support its feasibility in this vulnerable population.

### Conclusion:

The SOFT study provides strong evidence that short-course radiotherapy followed by delayed surgery is a feasible, effective, and well-tolerated alternative to standard chemoradiotherapy for older patients with locally advanced rectal cancer who are unable to undergo chemotherapy. This approach offers meaningful tumor control, favorable safety, and improved tolerability, addressing the unique needs of this patient population. It represents an important advancement in the management of elderly patients with rectal cancer, helping to standardize care for those who may otherwise struggle with conventional treatment regimens.

Related Q&A

KRAS ctDNA Predicts Outcomes After Neoadjuvant Therapy in PDAC: Annals of Surgery | July 2026

Introduction: Circulating tumor DNA (ctDNA) has emerged as a promising noninvasive biomarker for monitoring treatment response and residual disease in solid tumors. However, its prognostic value during neoadjuvant chemotherapy (NAC) for localized pancreatic ductal adenocarcinoma...

Low-Dose Aspirin for Lynch Syndrome: Lancet | July 2026

Introduction: Aspirin is one of the few interventions proven to reduce colorectal and other Lynch syndrome–associated cancers. The earlier CaPP2 trial established 600 mg daily aspirin as an effective chemopreventive strategy, but concerns regarding long-term...

4-Year Benefit of Durvalumab in BTC: JAMA Oncol | July 2026

Introduction: The TOPAZ-1 trial established durvalumab combined with gemcitabine and cisplatin (GemCis) as the first immunotherapy-based first-line standard of care for advanced biliary tract cancer (BTC). However, long-term survival outcomes and durability of benefit beyond...

The First Standardized PET Response Framework for Neuroendocrine Tumors: The Lancet Oncology | July 2026

Introduction: Somatostatin receptor (SSTR) PET/CT has become indispensable for diagnosing, staging, and monitoring neuroendocrine tumors (NETs). However, until now, there has been no standardized method for assessing treatment response using SSTR PET imaging. This international...

Staging Laparoscopy in Gastric Cancer: Annals of Surgical Oncology | July 2026

Introduction: Staging laparoscopy (SL) is recommended for patients with locally advanced gastric cancer to detect occult peritoneal metastases before curative treatment. However, its real-world utilization across Europe remains uncertain. This large GASTRODATA study evaluated the...

Celecoxib Boosts Neoadjuvant Immunotherapy in dMMR/MSI-H CRC : Lancet Oncol | Jul 2026

Introduction: Neoadjuvant immune checkpoint inhibitors have transformed the management of mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced colorectal cancer, achieving unprecedented pathological response rates. Experimental evidence suggests that cyclooxygenase-2 (COX-2) inhibition may enhance...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer